Concepedia

J. Lahmar

JL

10

Publications

2.1K

Citations

10

H-Index

2016

Active since

Affiliations

Institut Gustave Roussy(Current)

Hôpital Bichat-Claude-Bernard

Centre Hospitalier Intercommunal Toulon-La Seyne-sur-Mer

Institut Bergonié

Université Claude Bernard Lyon 1

J. Lahmar is an author at Institut Gustave Roussy specializing in oncology, medicine, and lung cancer.

Top concepts

Publications per year

2016–2020

10

Publications

10

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

Laura Mezquita, Édouard Auclin, Roberto Ferrara et al. · JAMA Oncology · 2018 · 925 citations · Full text

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Roberto Ferrara, Laura Mezquita, Matthieu Texier et al. · JAMA Oncology · 2018 · 719 citations · Full text

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

Mélodie Tazdait, Laura Mezquita, J. Lahmar et al. · European Journal of Cancer · 2017 · 337 citations

, , +6

Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non–Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy

Roberto Ferrara, Laura Mezquita, Matthieu Texier et al. · JCO Precision Oncology · 2020 · 37 citations · Full text

Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO)

Roberto Ferrara, Caroline Caramella, Matthieu Texier et al. · Annals of Oncology · 2017 · 28 citations · Full text

, , +7

Rows per page

1–5 of 10